Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech's Early Cancer Technology Scout On Partnering, Roche Setup & BD Challenges

Executive Summary

There is still much more to be learnt about cancer immunology, particularly what drives cancer cell growth, proliferation and resistance mechanisms, says Kevin Sin, Genentech's VP of oncology business development. Speaking to Scrip at the recent BIO-Europe Spring partnering conference, Sin describes Genentech's partnering strategy in oncology and how, almost a decade after the merger, Roche and Genentech are still working collaboratively and competitively to find the best new science in cancer.

You may also be interested in...



Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

Genentech's BD Exec Spotlights Neuroscience Pipeline

Thomas Zioncheck, business development executive at Genentech, outlines the company's upcoming R&D goals and early-stage partnering approach outside of oncology. He highlights Genentech's multiple sclerosis portfolio and adds color to its R&D strategy for products targeting Alzheimer's disease and other neurological conditions.

Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel